Associate Professor of Medicine

phone: 401-793-5700

E-mail: [email protected]

Academic Interests:

The focus of my research and clinical practice is fecal microbiota transplantation (FMT) for the treatment of C. difficile infection (CDI).  I am currently one of the Principal Investigators for an NIH-funded FMT national registry which will answer important questions around real-world efficacy and safety of FMT.  I assisted other physicians and institutions around the country in developing FMT protocols. I collaborate regionally, nationally and internationally with other physicians and scientists who have clinical and research interests in FMT. The goal is to move this novel treatment forward.  In addition, I have coauthored the current FMT guidelines, and I speak and serve on the scientific advisory board for the American Gastroenterological Association Center for Gut Microbiome Research and Education.  

 

Select Publications:

Manipulating the Microbiome With Fecal Transplantation to Treat Ulcerative Colitis. Kelly CR, Ananthakrishnan AN. JAMA. 2019 Jan 15;321(2):151-152. doi: 10.1001/jama.2018.20397. No abstract available. PMID: 30644970

The AGA's Fecal Microbiota Transplantation National Registry: An Important Step Toward Understanding Risks and Benefits  of Microbiota Therapeutics. Kelly CR, Kim AM, Laine L, Wu GD. Gastroenterology. 2017 Mar;152(4):681-684. doi: 10.1053/j.gastro.2017.01.028. Epub 2017 Jan 29. No abstract available. PMID: 28143773

Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection: A Randomized Trial.Kelly CR, Khoruts A, Staley C, Sadowsky MJ, Abd M, Alani M, Bakow B, Curran P, McKenney J, Tisch A, Reinert SE, Machan JT, Brandt LJ.Ann Intern Med. 2016 Nov 1;165(9):609-616. doi: 10.7326/M16-0271. Epub 2016 Aug 23. PMID: 27547925

Kelly C, Degli Esposti S:  Hyperemesis. In: McGarry KA, Tong IL, eds 5-Minute Consult Clinical Companion to Women’s Health. Philadelphia, PA: Lippincott, Williams and Wilkins; 2007 :238-240.

Kelly C:  “Molecular Biology of Liver Carcinogenesis and Hepatitis.”  Blumgart: In:  Surgery of the Liver, Biliary Tract and Pancreas, 4th ed.  In Press.

Kelly C:  “Inhibition of Cyclooxygenase-2 by Refecoxib Attenuates the Growth and Metastatic Potential of Colorectal Carcinoma in Mice.”  Cancer Research  63:586-592, February 1, 2003.